Although in developed countries the incidence of gastric cancer has dramatically decreased, gastric cancer is still a leading cause of cancer-related deaths worldwide. Surgery is the only potentially curative treatment. Although the survival rates for patients with early stage disease (stage 1A and 1B) are good, this subgroup of patients constitutes only 20% of those undergoing resection. Most patients have locally advanced or metastatic disease at presentation. The current 5-year survival rate for gastric cancer in Western countries is 20-30%, which has improved little over the past 30 years.

The primary objective of TOPGEAR is to investigate whether addition of chemoradiotherapy to neoadjuvant chemotherapy is superior to chemotherapy alone in improving the pathological complete response rates, and subsequently for overall survival.

Supported By:

Cancer Australia; NHMRC CTC; AGITG

Eligibility:

Patients with resectable gastric cancer suitable for these treatments

Registration ID:

ACTRN12609000035224

Participation:

Local

Australian Lead Group:

AGITG

Status:

Open

Activation Date:

29/09/2009

Chairs:

Prof. Trevor Leong (Australia)

Contact:

topgear.study@sydney.edu.au